Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease
SECAUCUS, N.J., April 22, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced the launch of a new blood biomarker test for phosphorylated tau 217, or p-tau217. P-tau217 is a biomarker associated with Alzheimer's Disease (AD), supported by research as useful for an early diagnosis of AD.
- P-tau217 is a biomarker associated with Alzheimer's Disease (AD), supported by research as useful for an early diagnosis of AD.
- With a physician's test order, patients may provide a blood draw for testing from any of Quest's 2,000 patient service centers in the United States.
- "We know diagnosing AD is challenging, and believe our AD Detect™ services can help individuals better understand their possible risk."
- A leader in neurology, Quest Diagnostics is committed to developing innovative laboratory services to aid in evaluating patient risk of Alzheimer's Disease and other dementias.